ArticleThe International journal on drug policy2022
Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting.
Article in The International journal on drug policy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- The Ethnopharmacological Use of Mescaline for Psychiatric Disorders: A Systematic Review.International journal of molecular sciences · 2026Pooled it
- The therapeutic effects of psychedelics for opioid use disorder: A systematic review of clinical studies.Psychiatry research · 2025Pooled it
- Exploring the therapeutic potential of psychedelics in treating substance use disorders.Molecular psychiatry · 2025Review
- A Systematic Review and Meta-Analysis Investigating the Efficacy of Various Psychedelic Drugs for the Treatment of Substance Use Disorder.Healthcare (Basel, Switzerland) · 2025Review
- Perspectives on Trauma Treatment, Self-Management Strategies, and Attitudes Toward Psychedelic Therapies in Individuals with Psychological Trauma Symptoms.Psychiatry and clinical psychopharmacology · 2025Article
- LSD Restores Synaptic Plasticity in VTA of Morphine-Treated Mice and Disrupts Morphine-Conditioned Place Preference.bioRxiv : the preprint server for biology · 2025Article
- Race/ethnicity moderates the associations between lifetime psilocybin use and opioid use disorder.PloS one · 2025Article
- From taboo to treatment: The emergence of psychedelics in the management of pain and opioid use disorder.British journal of clinical pharmacology · 2024Review
- Psychedelic substitution: altered substance use patterns following psychedelic use in a global survey.Frontiers in psychiatry · 2024Article
- Psychedelics: From Cave Art to 21st-Century Medicine for Addiction.European addiction research · 2024Review
- Hallucinogenic potential: a review of psychoplastogens for the treatment of opioid use disorder.Frontiers in pharmacology · 2023Review
- Psychedelic therapy in the treatment of addiction: the past, present and future.Frontiers in psychiatry · 2023Review
- μ-opioid receptor agonists and psychedelics: pharmacological opportunities and challenges.Frontiers in pharmacology · 2023Review
- The psychedelic remedy for chronic pain.Nature · 2022Article
- Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample.Scientific reports · 2022Article
- The association between naturalistic use of psychedelics and co-occurring substance use disorders.Frontiers in psychiatry · 2022Article
- Developing non-opioid therapeutics to alleviate pain among persons with opioid use disorder: a review of the human evidence.International review of psychiatry (Abingdon, England)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundResearch into the therapeutic and naturalistic uses of psychedelics for improving outcomes related to mental health disorders has generated increasing interest in recent years. While controlled clinical trials of psychedelics have signaled benefits for treating substance use disorders, this area has not been well studied in the context of naturalistic psychedelic use. This study sought to investigate the possible relationship between recent naturalistic psychedelic use and subsequent daily illicit opioid use among people who use drugs (PWUD).
methodsData (2006-2018) were drawn from three harmonized prospective cohorts of community-recruited PWUD in Vancouver, Canada. We used multivariable generalized linear mixed-effects modeling (GLMM) to estimate the independent association between psychedelic use and subsequent daily illicit opioid use.
resultsAmong 3813 PWUD at baseline, 1093 (29%) reported daily use of illicit opioids and 229 (6%) reported psychedelic use in the past six months. Over study follow-up after adjusting for a range of potential confounders, psychedelic use remained independently associated with a significantly reduced odds of subsequent daily opioid use (Adjusted Odds Ratio: 0.45; 95% Confidence Interval: 0.29 to 0.70).
conclusionWhile confirmation in other settings is required, these findings align with growing evidence that psychedelic use may be associated with detectable reductions in subsequent substance use including illicit opioid use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.